# Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma

> **NCT05439278** · PHASE3 · RECRUITING · sponsor: **Severance Hospital** · enrollment: 178 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **RADIATION:** Hypofractionated radiotherapy
- **RADIATION:** Conventional radiotherapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05439278
- **Lead sponsor:** Severance Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05439278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05439278, "Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05439278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*